Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial of Emricasan, an Oral Caspase Inhibitor, in Subjects With Non-Alcoholic Steatohepatitis (NASH) Cirrhosis and Severe Portal Hypertension

NCT02960204 is registered in ClinicalTrials.gov with Histogen as lead sponsor.

NCT NCT02960204
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02960204 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial of Emricasan, an Oral Caspase Inhibitor, in Subjects With Non-Alcoholic Steatohepatitis (NASH) Cirrhosis and Severe Portal Hypertension
Lead sponsor
Histogen
Phase
Phase 2
Overall status
Completed
Start date
October 17, 2016
Completion date
April 8, 2019
Enrollment
263 (actual)
Sites
37

Conditions

As the registry lists them; a condition with its own page is linked.

cirrhosis, non-alcoholic steatohepatitis, portal hypertension